PTPN6

So the first is biological selectivity.

So synthetic lethality limits the drug's lethality to cells that have already lost P10 or SHP1.

It limits the lethality to only those cells.

Healthy cells that have not lost them don't experience this toxic effect of the drug.

So first, our particular target is uncontested.

Second, the biomarker.

Loss of P10 or SHP1 is somatic and common across many tumor types, rather than a narrow population defined by a germline mutation, so our selectable group is larger for synthetic lethality.

Third, the compound also operates as a broad sensitizer to standard treatments, where most DNA damage response assets operate either through synthetic lethality or sensitization.